Express Pharma Breaking News Headlines Today | Ground News

Express Pharma image

News from Express Pharma

Your destination for news from Express Pharma. See how Express Pharma’s media bias impacts the breaking news stories of today.

We’ve aggregated 262 of Express Pharma’s headlines and news stories over the past 3 months.

Ground News rates Express Pharma’s media bias as . . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Express Pharma’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Express Pharma

Where is Express Pharma located?Express Pharma's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Express Pharma News

Celltrion leads biosimilars deals landscape in South Korea, finds GlobalData

Infrastructure · South Korea

Celltrion leads biosimilars deals landscape in South Korea, finds GlobalData

South Korea has emerged as a global leader in the biopharmaceutical industry, driven by its advanced clinical research infrastructure and government support. Key companies like Celltrion and Samsung Bioepis dominate the biosimilars market, contributing significantly to the approvals and pipelines. Celltrion’s strong presence in deal-making further underscores South Korea’s growing influence in the global biosimilars landscape, reveals GlobalData…See the Story

Granules India's Generic ADHD Drug Gets FDA Nod

Granules India's Generic ADHD Drug Gets FDA Nod

Drug maker Granules India Ltd. announced on Tuesday that its subsidiary, Granules Pharmaceuticals Inc., has received approval from the US Food and Drug Administration for a generic version of a medication used to treat attention-deficit hyperactivity disorder.The approval pertains to GPI's abbreviated new drug application for Lisdexamfetamine Dimesylate chewable tablets, the company said in an exchange filing. The generic product will be availab…See the Story

How Eczema Treatments Have Changed

How Eczema Treatments Have Changed

This isn't your mom's eczema treatment. The post Treating Eczema in 2024 Is a Whole Different Game appeared first on NewBeauty.See the Story

Latest News Stories

You've scrolled to the bottom of the feed, there are no more stories.

Donate Privacy Policy Manage Cookies Terms and Conditions

© 2024 Snapwise Inc